ADRB1 and esophageal squamous cell carcinoma: Our study suggests that elevated expression of ADRB1 after neoadjuvant immune chemotherapy correlates with poorer prognosis in ESCC patients, indicating that ADRB1 could serve as an important biomarker for assessing the efficacy of this treatment strategy.